Friday, April 22, 2022 12:17:24 PM
People throw that word around a lot. Incompetence.
Have you ever tried to list on one side the things you think are incompetence, and on the other side the things you think he's done right?
Do yo really think he's hitting the pavement and trying to sell to WalMart himself?
No, it's the Private Label Partners that are hitting the pavement.
So what happens if THEY don't sell anything, or THEIR projections fall flat?
Answer...SHMN doesn't sell as much. That simple.
I've made a list, and yes Baron is not perfect. But he's not incompetent either. Check the list.
The problem in the OTC, is traders want to compare the one they are bagged in, to others that are projecting grandiose Revenues, or the smaller few that do in fact have larger Revenues, and they are saying well since by bag doesn't have that much Revs, my CEO must be incompetent.
My opinion, each company has to be weighed individually, not in comparison.
Read my other posts also, to see what I was referring to. Bidders want your shares.
SHMN is a tiny Pharma, and growing, that's it. Until we see what the FDA advisors are for,...
hl shmn
Have you ever tried to list on one side the things you think are incompetence, and on the other side the things you think he's done right?
Do yo really think he's hitting the pavement and trying to sell to WalMart himself?
No, it's the Private Label Partners that are hitting the pavement.
So what happens if THEY don't sell anything, or THEIR projections fall flat?
Answer...SHMN doesn't sell as much. That simple.
I've made a list, and yes Baron is not perfect. But he's not incompetent either. Check the list.
The problem in the OTC, is traders want to compare the one they are bagged in, to others that are projecting grandiose Revenues, or the smaller few that do in fact have larger Revenues, and they are saying well since by bag doesn't have that much Revs, my CEO must be incompetent.
My opinion, each company has to be weighed individually, not in comparison.
Read my other posts also, to see what I was referring to. Bidders want your shares.
SHMN is a tiny Pharma, and growing, that's it. Until we see what the FDA advisors are for,...
hl shmn
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
